Cite
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
MLA
Bekaii-Saab, Tanios, et al. “Multi-Institutional Phase II Study of Selumetinib in Patients with Metastatic Biliary Cancers.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 29, no. 17, June 2011, pp. 2357–63. EBSCOhost, https://doi.org/10.1200/JCO.2010.33.9473.
APA
Bekaii-Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L., Kauh, J. S. W., O’Neil, B. H., Balsom, S., Balint, C., Liersemann, R., Vasko, V. V., Bloomston, M., Marsh, W., Doyle, L. A., Ellison, G., Grever, M., Ringel, M. D., & Villalona-Calero, M. A. (2011). Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 29(17), 2357–2363. https://doi.org/10.1200/JCO.2010.33.9473
Chicago
Bekaii-Saab, Tanios, Mitch A Phelps, Xiaobai Li, Motoyasu Saji, Laura Goff, John Sae Wook Kauh, Bert H O’Neil, et al. 2011. “Multi-Institutional Phase II Study of Selumetinib in Patients with Metastatic Biliary Cancers.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 29 (17): 2357–63. doi:10.1200/JCO.2010.33.9473.